Submissions from 2025
62783 Beyond 7 years: Investigating Diagnostic Delay of Hidradenitis Suppurativa at an Urban Tertiary Care Dermatology Clinic, Deena Abdel-Gadir, Mavra Masood, Mohsen Mokhtari, Jaina Gaudette, Kameryn Abraskin, Jasira Ziglar, Iltefat Hamzavi, and Richard Huggins
64482 Optimization of Acquisition Techniques and Image Analysis in Optical Polarization Imaging for Basal Cell Carcinoma Margin Detection Prior to Mohs Surgery, Kamryn Abraskin, Jaina Gaudette, Mohsen Mokhtari, Brittani Jones, Monica Rosales Santillan, John Wuennenberg, Tyler Lorizzo, Anna Yaroslavsky, David Ozog, and Indermeet Kohli
Occupational Allergic Contact Dermatitis in Manicurists: A Systematic Review, Nicholas Belair and Holly A. Kerr
0305 Topical and oral phosphodiesterase-4 inhibitors for refractory seborrheic dermatitis: A systematic review, Zane M. Berry, Meghan R. Mansour, and Joseph W. Fakhoury
0061 Interstitial granulomatous dermatitis: A case highlighting possible associations with myeloma and TNF-α inhibitor therapy, Zane M. Berry, Karan Pandher, Mustafa Jafry, and Marsha Chaffins
Skin clearance, treatment response off-therapy, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week Phase 3 trial in adults and children down to 2 years of age with atopic dermatitis, Robert Bissonnette, Linda F. Stein Gold, Leon Kircik, Eric Simpson, Lawrence F. Eichenfield, John Browning, Adelaide A. Hebert, Andrew F. Alexis, Weily Soong, Stephen C. Piscitelli, Anna M. Tallman, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
62846 Efficacy of deucravacitinib in psoriasis by baseline total body surface area: post hoc analysis of the randomized, double-blind, placebo-controlled, phase 3b/4 PSORIATYK Scalp trial, Andrew Blauvelt, Matthias Hoffman, Linda F. Stein Gold, Jerry Bagel, Mark Lebwohl, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, and Christopher E. M Griffiths
64608 Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis, Andrew Blauvelt, Bruce Strober, Gaia Gallo, Yuxin Ding, Yun-Fei Chen, Martin Dossenbach, Lidia R. Calleja, Linda F. Stein Gold, and Jonathan Silverberg
64584 Skin of Color Society (SOCS) Project to Develop Inclusive Skin Assessment Tools, Valerie Callender, Andrew Alexis, Seemal Desai, Tarannum Jaleel, Henry W. Lim, Rashmi Sarkar, Susan Taylor, Jadesola Akanji, Hiba Mohammed, and Valerie Harvey
Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in hispanic participants with moderate-to-severe acne, Valerie D. Callender, Hilary Baldwin, Linda F. Stein Gold, Fran E. Cook-Bolden, and Andrew F. Alexis
60502 Design and Rationale of ARMADA-AD Disease Registry: An International, Prospective, Observational Registry to Characterize Unmet Needs and Evaluate Real-World Effectiveness and Safety of Systemic Therapies in Adults and Adolescents with Atopic Dermatitis, Raj Chovatiya, Bob Geng, Thomas Bieber, Linda F. Stein Gold, Diamant Thaçi, Moataz Daoud, Kassim Rahawi, and Gopinath Nageshwaran
64222 Allergen Content in Best-Selling Sunscreens: A Comparison of Key Product Features, Christopher Chung, Emily Levin, Katia Hermes, Judy Hamad, Henry W. Lim, and Natalie Matthews
0680 Proteomics identifies blood biomarkers associated with disease severity and genetic ancestry in hidradenitis suppurativa, Peter Dimitrion, Rachel Krevh, Jesse Veenstra, Iltefat Hamzavi, Indra Adrianto, Li Zhou, and Qing-Sheng Mi
0680 Proteomics identifies blood biomarkers associated with disease severity and genetic ancestry in hidradenitis suppurativa, Peter Dimitrion, Rachel Krevh, Jesse Veenstra, Iltefat Hamzavi, Indra Adrianto, Li Zhou, and Qing-Sheng Mi
64656 52-Week Disease Control and Safety With As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years With Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis From the TRuE-AD3 Study, Lawrence F. Eichenfield, Eric L. Simpson, April W. Armstrong, Linda F. Stein Gold, Lara W. Lee, Kanwaljit K. Brar, Joel C. Joyce, Brett Angel, Daniel Sturm, Haobo Ren, and Andrea Zaenglein
64595 Embolia Cutis Medicamentosa: An Underrecognized Diagnosis Associated with Injectable Medication Use, Maria Espinosa, Saloni Shah, Karla Navarro, and Alison Boucher
62005 Characterizing suspected and confirmed drug-resistant dermatophytosis through the launch of the AAD/ILDS Drug Resistant Dermatophytes Registry, Esther Freeman, Morvarid Zehtab, Sidra Khan, Ditte Saunte, Avrom Caplan, Christine Li, Seemal Desai, and Henry W. Lim
Early acne improvements with fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel: What to expect in the first 4 weeks of treatment, Julie C. Harper, Leon H. Kircik, Michael Gold, Adelaide A. Hebert, Jeffrey L. Sugarman, Lawrence Green, Linda F. Stein Gold, Hilary Baldwin, James Q. Del Rosso, and Eric Guenin
0517 scRNA-seq identifies atopic dermatitis development marked by early neutrophils and T cell shifts in filaggrin-null mice with environmental sensitivity, Autumn Hicks, Mohammed H. M Barmal, A. Schmidt, Q. Zheng, Congcong Yin, Peter Dimitrion, Qing-Sheng Mi, Aimin Jiang, E. Grice, Indra Adrianto, and Cristina de Guzman Strong
0969 Exploring BMI-associated gene expression patterns in hidradenitis suppurativa lesions through transcriptional profiling, Sahil Kapur, Jeffrey Cruz, Randy Mi, Xzaviar K. Solone, Meyer Gershater, Iltefat Hamzavi, Indra Adrianto, and Qing-Sheng Mi
61571 Cryofibrinogenemia secondary to multiple myeloma presenting as digital necrosis, Mardeen S. Karim, Ben J. Friedman, and Sasank Konda
61909 Evidence-based hair care products and practices to use while scalp cooling, Lily Kaufman, Lucy Rose, Olivia Ueltschi, Samantha Rojas, Kateri Schoettinger, Madison Novice, Taylor Novice, Kimberly Salkey, Maria Hordinsky, and Brittany Dulmage
63465 A Comparison of the Risk of Major Cardiovascular Events, Venous Thromboembolism, Serious Infections, and Malignancies Among Patients With Vitiligo in the United States Using Real-World Data, Brett King, Viktoria Eleftheriadou, Claire C. Bristow, Danielle M. Conrad, Nada Elbuluk, Albert Wolkerstorfer, Harvey Lui, Emma Yue, Sarah Ofori, Thierry Passeron, and Iltefat Hamzavi
63755 Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: Efficacy and Safety Results from 4 Clinical Trials, Leon H. Kircik, Zoe D. Draelos, Edward Lain, Julie C. Harper, Hilary Baldwin, Linda F. Stein Gold, Michael Gold, and Eric Guenin
Deucravacitinib in plaque psoriasis: laboratory parameters through 4 years of treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE trials, Neil J. Korman, Thierry Passeron, Yukari Okubo, Jerry Bagel, Richard B. Warren, Lynda Spelman, Kevin Winthrop, Kim Hoyt, Thomas Scharnitz, Subhashis Banerjee, Diamant Thaçi, Mona Shahriari, and Linda F. Stein Gold
Impact of risankizumab on disease symptoms in patients with non-pustular palmoplantar psoriasis: Post hoc analysis of the phase IIIb IMMprint study, Mark Lebwohl, Michael Bukhalo, Linda F. Stein Gold, Brad Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, David Cotter, Anqi Pan, Cuiyong Yue, Manish Patel, Ramon Espaillat, Blair Kaplan, Lynda Spelman, and Robert Bissonnette
61479 Pigmentary disorders, prevalence, impact on quality of life, social stigmatization: results of the first large international survey in North America (I'SPOT study), Henry W. Lim, Andrew Alexis, Sergio Schalka, Brigitte Dréno, Jean Krutmann, Jorge O. Candiani, Caroline Le Floc'h, Delphine Kerob, Thierry Passeron, and Khaled Ezzedine
0419 Exposure risk of sunburns in the development of keratinocyte carcinoma: A meta analysis, Jalal Maghfour, J. Meisenheimer, M. Hook-Sobotka, and R. Dellavalle
63530 Pseudoporphyrias: A Systematic Review and Meta-analysis, Meghan Mansour, Madison Romanski, Nicholas Belair, Mohsen Mokhtari, and Joseph Fakhoury
Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study, Vinay Mehta, Linda Stein-Gold, Alexandra Golant, Peter Lio, Raj Chovatiya, Zach Dawson, Evangeline Pierce, Louise A. DeLuca-Carter, James Haughton, James Piercy, Peter Anderson, and Bob Geng
0203 HS progress: Baseline characteristics and disease impact, V. Nielsen, M. Lowes, A. Yates, A. Alavi, R. Flowers, Iltefat Hamzavi, J. Kirby, R. Micheletti, C. Sayed, and H. Naik
0756 Cannabidiol as a potential sunscreen additive: A survey of peer-reviewed literature, G. G. Papadeas, M. Szeto, M. Reed, Andrina Paul, T. M. Runion, J. Anderson, and R. Dellavalle
0643 TAK1 regulates langerhans cell homeostasis through MAPK and ER stress-activated autophagic machinery, Nirmal Parajuli, Qiyan Wang, Qian Yu, Qing-Sheng Mi, and Li Zhou
61478 Pigmentation disorders in North America Results of International Survey on Pigmentation-disorders Observational Tracking [I'SPOT] study, Thierry Passeron, Andrew Alexis, Brigitte Dréno, Sergio Schalka, Jorge O. Candiani, Caroline Le Floc'h, Delphine Kerob, Jean Krutmann, Henry W. Lim, and Khaled Ezzedine
61480 The interplay of pigmentation disorders and phototype in shaping perceived stigmatization: findings from the I'SPOT survey, Thierry Passeron, Andrew Alexis, Samir Salah, Akimichi Morita, Brigitte Dréno, Sergio Schalka, Delphine Kerob, Jean Krutmann, Henry W. Lim, and Khaled Ezzedine
62661 Dupilumab as a Therapeutic Approach for Keloids: A Review of Current Evidence, Akash Rau, Karan Pandher, David Gao, and Natalie Matthews
63170 Analysis of oral, topical, and compounded minoxidil prices and insurance coverage, Lucy Rose, Samantha Rojas, Sonja Kobayashi, Olivia Ueltschi, Stephanie Adame, Kimberly Salkey, Maria Hordinsky, and Brittany Dulmage
60359 Utilizing Health Savings Accounts to Enhance Dermatological Care: Eligibility and Benefits, Sarah Shareef, Disha Bhargava, and Kurt Ashack
Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt trial, Jonathan I. Silverberg, Lindsay Ackerman, Jerry Bagel, Linda F. Stein Gold, Andrew Blauvelt, David Rosmarin, Raj Chovatiya, Matthew Zirwas, Gil Yosipovitch, Jill Waibel, Jenny E. Murase, Ben Lockshin, Jamie Weisman, Amber R. Atwater, Cynthia Harris, Jennifer Proper, Maria Silk, Evangeline Pierce, Maria L. Buziqui Piruzeli, Sonia Montmayeur, Christopher Schuster, Jinglin Zhong, Maria J. Rueda, Sreekumar Pillai, and Eric Simpson
64513 Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 – Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te, Jonathan I. Silverberg, Linda F. Stein Gold, Diamant Thaci, Andrew Pink, Kim Papp, Franz J. Legat, Soo Yeon Cheong, Anna Ryzhkova, Liliana Ulianov, and Christophe Piketty
Efficacy and Safety of Ruxolitinib Cream Monotherapy in Patients Aged 2 Years and Older With Mild-to-Moderate Atopic Dermatitis: Results From 3 Large Randomized Phase 3 Studies, Eric Simpson, Lawrence Eichenfield, Kim Papp, Leon Kircik, Andrew Blauvelt, Linda F. Stein Gold, Andrea Zaenglein, Lara W. Lee, Christopher Bunick, Seth Forman, Kristen Holl, Howard Kallender, Daniel Sturm, Haobo Ren, and April Armstrong
64775 Integrated Safety Update of Abrocitinib in 1014 Young Adult Patients Aged 18 to <40 Years With Moderate-to-Severe Atopic Dermatitis: Data From More Than 2250 Patient-Years With up to 4.5 Years of>Exposure, Eric Simpson, Alan D. Irvine, Jonathan I. Silverberg, Linda F. Stein Gold, Michael J. Cork, Mette Deleuran, Bob Geng, Cristina Lumpan, Andrew Selfridge, Haiyun Fan, and Herwig Koppensteiner
0152 IFNg-mediated reprogramming of antigen presenting cell (IMRAPC) behavior in keratinocytes is perturbed in skin cancer, Niharika Srivastava, Angelica Guardia De Diego, Mohammad H. Barmal, Indra Adrianto, Jesse Veenstra, and Cristina de Guzman Strong
63324 Efficacy of zasocitinib (TAK-279), an oral, allosteric, potent and selective TYK2 inhibitor, evaluated by Physician's Global Assessment×Body surface area (PGA×BSA), in a randomized phase 2b trial in moderate-to-severe plaque psoriasis, Linda F. Stein Gold, Lawrence Green, Jessamyn Blau, Wenwen Zhang, Jonathan Uy, Warren Winkelman, and Leon Kircik
63474 The VISIBLE study: Burden of comorbidities in participants with moderate-to-severe psoriasis across all skin tones, Linda F. Stein Gold, George Han, Mona Shahriari, Olivia Choi, Theodore Alkousakis, Tony Ma, Daphne Chan, Lawrence Green, Aaron Farberg, Shawn G. Kwatra, and Andrew Alexis
63046 Tapinarof Cream 1% Once Daily for Atopic Dermatitis: Validated Investigator Global Assessment for Atopic Dermatitis™ x Body Surface Area (vIGA-AD™xBSA) Composite in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age, Linda F. Stein Gold, Rocco T. Serrao, G. Michael Lewitt, Anna M. Tallman, David S. Rubenstein, and Philip M. Brown
63736 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement, Linda F. Stein Gold, Bruce Strober, April W. Armstrong, Theodore Alkousakis, Kim A. Papp, Richard Langley, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Vlada Groysman, and Mark G. Lebwohl
Tapinarof Cream 1% Once Daily: Consistent Efficacy Across All Body Regions, Including Head And Neck, In Adults And Children Down 2 Years Of Age With Atopic Dermatitis, Anna Tallman, Justin Greiwe, J. Wesley Sublett, Adelaide Hebert, David Rosmarin, Philip Brown, David Rubenstein, and Linda F. Stein Gold
LEBRIKIZUMAB IMPROVES ATOPIC DERMATITIS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB: RESULTS FROM THE ADAPT STUDY, Elisabeth H. Taudorf, Jonathan Silverberg, Lindsay Ackerman, Jerry Bagel, Linda F. Stein Gold, Andrew Blauvelt, David Rosmarin, Raj Chovatiya, Matthew Zirwas, Gil Yosipovitch, Jill Waibel, Jenny Murase, Ben Lockshin, Jamie Weisman, and Eric Simpson
62860 Achievement of treat-to-target thresholds for overall psoriasis response with deucravacitinib: post hoc, subgroup analysis of the randomized, double-blind, placebo-controlled phase 3b/4 PSORIATYK SCALP trial, Diamant Thaci, Kristina C. Duffin, Linda F. Stein Gold, Leon Kircik, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, and Matthias Augustin
Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis, Diamant Thaçi, Lluis Puig, Kim Papp, Linda F. Stein Gold, Pablo Fernández-Peñas, Yu-Huei Huang, Martin Dossenbach, Meritxell Falqués, Helena Agell, Franziska Schönherr, and Christian Vestergaard
61710 Dermatology pathways programs and increasing provider representation, Reinie Thomas, Marina Khreizat, Brittany Lane, Karan Pandher, Severine Cao, Henry W. Lim, and Natalie H. Matthews
MEAN ABSOLUTE EASI AND PRURITUS ACHIEVED BY LEBRIKIZUMAB OVER 16 WEEKS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS, Christian Vestergaard, Diamant Thaci, Luis Puig, Kim A. Papp, Linda F. Stein Gold, Pablo F. Peñas, Yu-Huei Huang, Martin Dossenbach, Meritxell Falques, Helena Agell, and Kristian Gaarn Du Jardin
0650 Dysregulated innate MAIT cells in patients with hidradenitis suppurativa, Ping Wang, Jugmohit Toor, Peter Dimitrion, Iltefat Hamzavi, Indra Adrianto, Qing-Sheng Mi, and Li Zhou
63960 Surgical location affects preoperative anxiety in Mohs micrographic surgery: a prospective interventional study, Josiah Williams, Veronica Emmerich, Shane Reynal, Courtney Heron, Stephanie Snyder, Matthew Johnson, Rima Ghamrawi, Emily Unrue, and Steven Feldman
64991 Surgical location affects preoperative anxiety in Mohs micrographic surgery: an interventional study, Josiah Williams, Veronica Emmerich, Shane Reynal, Courtney Heron, Stephanie Snyder, Matthew Johnson, Rima Ghamrawi, Emily Unrue, Jessica Savas, Phillip Williford, and Steven Feldman
63916 Idiopathic CD4+ T Cell lymphocytopenia associated with a chronic recalcitrant erythroderma resembling pityriasis rubra pilaris, Nikita Wong, Karan Pandher, and Ben J. Friedman
62644 Analysis of Popular Sunscreens for Babies and Children: Ingredient Profiles and Marketing Tactics, Marissa Yaldo, Meghan Mansour, Hailey Olds, and Geoffrey Potts
0519 Involucrin-casein kinase 1e-vitamin D receptor is a functional regulatory axis for human skin evolution and diversity, Yao Yao, Autumn Hicks, A. Schmidt, M. Mathyer, and Cristina de Guzman Strong
61429 Adherence to melanoma surveillance guidelines: real-world practice and implications for patient outcomes, Albert T. Young, Rita El Jbeily, Brittany N. Lane, Katia Hermes, Madison Romanski, Flavio Ago, Andrea Dai, J. Gregory Hixon, Martin A. Weinstock, Charles N. Ellis, and Natalie H. Matthews
0278 Whole blood RNA-Seq identifies key pathways linked to TNF-α-inhibitor failure in patients with hidradenitis suppurativa, Albert T. Young, Randy Mi, Ping Wang, Anuradha Bishnoi, Andrea Dai, Kermanjot S. Sidhu, Suzanne Shoffner-Beck, Jeffrey Cruz, Sahil Kapur, Li Zhou, Indra Adrianto, and Qing-Sheng Mi
62587 Adherence to Breast Cancer Screening Guidelines Among Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study, Albert T. Young, Umer Nadir, Alexandra Turfe, Meyer Gershater, Mulin Xiong, and Qing-Sheng Mi
61220 Analysis of patients with hidradenitis suppurativa from a large, single-center Detroit cohort: a retrospective cross-sectional study of 13,130 patients over a 27-year period, Kelly Young, Ian Loveless, Wan-Ting Su, Jesse Veenstra, Li Zhou, Iltefat Hamzavi, Indra Adrianto, and Qing-Sheng Mi
Submissions from 2024
51125 PATIENT EXIT INTERVIEWS ILLUSTRATE BENEFIT OF TRIFAROTENE ON ACNE-INDUCED PIGMENTARY PROBLEMS, Andrew Alexis, James Del Rosso, Seth Forman, Antonio Calatayud, John Browning, Vivian Laquer, J. P. York, Rajeev Chavda, Sunil Dhawan, Angela Moore, and Linda Stein-Gold
53113 Trifarotene shown to improve acne and related sequelae (scars, pigmentation), Andrew Alexis, Stephen Schleicher, Jonathan Weiss, Valerie Callender, J. P. York, Rajeev Chavda, Fran E. Cook Bolden, Neal Bhatia, James Del Rosso, and Linda Stein-Gold
53447 Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types, Andrew Alexis, Linda Stein-Gold, Rajeev Chavda, J. P. York, James Del Rosso, and Jonathan Weiss
54147 Efficacy of Ruxolitinib Cream for Treatment of Atopic Dermatitis in Children Aged 2–<12 Years by Baseline Clinical Characteristics: Subgroup Analysis From a Randomized Phase 3 Study>(TRuE-AD3), April W. Armstrong, Lawrence F. Eichenfield, Lara W. Lee, Kanwaljit K. Brar, Joel C. Joyce, Seth B. Forman, Weily Soong, Howard Sofen, Brett Angel, Qian Li, and Linda Stein-Gold
Dermatology personal statement themes and match outcomes, Redina Bardhi, L. Bugosh, M. Al-Hadidi, J. Duong, S. Colbert, B. Jones, and S. Daveluy
54396 Ultrasound Mapping for Carbon Dioxide Surgery in Hidradenitis Suppurativa, Redina Bardhi, Mohsen Mokhtari, Mavra Masood, Iltefat Hamzavi, and Indermeet Kohli
52726 Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II, Falk G. Bechara, Christopher Sayed, Stephanie Goldberg, Jacek C. Szepietowski, Philippe Guillem, Iltefat Hamzavi, Pratiksha Dokhe, Paulatsya Joshi, Robert Rolleri, Leah Davis, and Hessel H. van der Zee
53894 Roflumilast foam 0.3% once daily in patients with seborrheic dermatitis: Improvement in patient reported outcomes and pruritus from a phase 3 trial (STRATUM), Neal Bhatia, Fran Cook-Bolden, Janet DuBois, Laura Ferris, Linda Stein-Gold, Irina Turchin, Matthew Zirwas, David Krupa, Patrick Burnett, David R. Berk, and David H. Chu
Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2-11 years: 52 week results from a maximum-use trial, Robert Bissonnette, Mark S. Lee, Seth B. Forman, Linda F. Stein Gold, Howard Kallender, Brett Angel, Yutzu Kuo, and Amy S. Paller
Tapinarof cream 1% once daily: Interim analysis of ADORING 3 phase 3 long-term extension trial in adults and children down to age 2 years with atopic dermatitis, Robert Bissonnette, Linda F. Stein Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
53928 Tapinarof Cream 1% Once Daily: Interim Analysis of ADORING 3 Phase 3 Long-term Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis, Robert Bissonnette, Linda Stein-Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, and Jonathan I. Silverberg
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis, Christopher G. Bunick, Neal Bhatia, James Del Rosso, Zoe D. Draelos, Lawrence F. Eichenfield, Leon H. Kircik, Mark G. Lebwohl, Melinda Gooderham, Lawrence J. Green, Adelaide A. Hebert, Ronald B. Vender, Matthew Zirwas, Eric L. Simpson, Linda F. Stein Gold, Melissa Seal, Scott Snyder, David W. Osborne, Patrick Burnett, Robert C. Higham, David H. Chu, and David R. Berk
50584 Online Continuing Medical Education Improved Dermatologists’ Knowledge, Competence, and Confidence About New Topical Treatments for Psoriasis, Shari Dermer, Christine Considine, Karen Badal, and Linda Stein-Gold
54214 Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children Aged 2–<12 Years by Previous Medication History: Subgroup Analysis From the>Randomized, Phase 3 TRuE-AD3 Study, Shari Dermer, Christine Considine, Karen Badal, and Linda Stein-Gold
Global survey reveals demand for additional photoprotection education in Australia...Cancer Nurses Society of Australia (CNSA) 26th Annual Congress, June 19-21, 2024, Brisbane, Queensland, L. Dousset, K. Khosrotehrani, P. Guitera, T. Passeron, B. Dreno, Henry W. Lim, D. Kerob, and J. Krutmann
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study, Lawrence F. Eichenfield, April W. Armstrong, Linda F. Stein Gold, Andrea L. Zaenglein, Lara Wine Lee, Kanwaljit K. Brar, Joel C. Joyce, Kristen E. Holland, Brett Angel, Daniel Sturm, Qian Li, and Eric L. Simpson
51626 Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From a Phase 2 Upadacitinib Study in Adults With Nonsegmental Vitiligo, Khaled Ezzedine, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, and Iltefat Hamzavi
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study, Melinda J. Gooderham, Stephan Weidinger, Eric L. Simpson, Mette Deleuran, Linda F. Stein Gold, Saleem A. Farooqui, Pinaki Biswas, Gary Chan, Erman Güler, and Herwig Koppensteiner
53495 Disparity of cost and protective features between tinted and non-tinted sunscreens, Judy Hamad, Christopher Chung, Henry W. Lim, and Natalie H. Matthews
PCR163 Treatment Priorities and Unmet Need Among Adults and Adolescents With Non-Segmental Vitiligo in the United States, Iltefat Hamzavi, J. Coulter, A. Balaji, L. Franco, S. Darnell, E. Law, S. Kurosky, R. Adiri, N. Elbuluk, and B. Hauber
51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo, Iltefat Hamzavi, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, and Khaled Ezzedine
54585 Vitiligo, Nutrition and the Gut Microbiome: A Narrative Review, Marlee Hewitt, Karan Pandher, Nada Elbuluk, and Richard Huggins
Environment impacts the phenotypic severity of flaky tail, MC903-induced inflammation, and dysbiosis in filaggrin-null mice, Autumn Hicks, Mohammed H. M Bharmal, A. Schmidt, Q Zheng, Congcong Yin, Peter Dimitrion, Qing-Shing Mi, Emelia Grice, Indra Adrianto, and Cristina de Guzman Strong
54843 QR Codes and Dermatology: Examining Resident Attitudes on Digitized After Visit Summaries, Mustufa Jafry, Joseph Fakhoury, and Holly Kerr
54853 Trends in Incidence and Mortality of Pleomorphic Dermal Sarcoma: A Retrospective Cohort Study Using SEER Data, Mustufa Jafry and Molly Powers
54772 Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey, Delphine Kerob, Thierry Passeron, Andrew Alexis, Brigitte Dreno, Liu Wei, Akimichi Morita, Chee Leok, Susana Puig, Sergio Schalka, and Henry W. Lim
54542 Assessing the risk of subcutaneous nodules, Rachel Krevh, Redina Bardhi, Karan Pandher, Gordon Jacobsen, and Laurie Kohen
53329 Long-Term Adverse Event Risks of Systemic Janus Kinase (JAK) Inhibitors versus Traditional Immunomodulators, Olivia Lamberg, Karan Pandher, and Henry Lim
51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial, Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Maria Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, and Robert Bissonnette
51675 Safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement: changes in PPASI and PASI from Phase 3b IMMprint trial, Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, and Robert Bissonnette
52818 Easy on the Hands: Utilization of a Foot Pedal for Tumescent Anesthesia Delivery, Mavra Masood, Joseph Fakhoury, Angela Parks-Miller, and Iltefat Hamzavi
52910 Projected burden of melanoma clinical surveillance in the United States, Natalie Matthews, Judy Hamad, James Henderson, Angela Mariotto, Martin Weinstock, and Charles Ellis
50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis, Amy McMichael, Linda Stein-Gold, Jennifer Soung, Chesahna Kindred, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Candrice R. Heath, Tina Bhutani, Maxwell Sauder, and Andrew Alexis
54078 Examining Hair Preservation in Manual vs. Machine Scalp Cooling by Chemotherapy Regimen: A Meta-Analysis, Abena Minta, Sarah Shareef, Patrick Schnell, Trevor Nessel, Lucy Rose, Brittany Dulmage, and Taylor Novice
52736 Assessment of Color Match of Universal Tinted Sunscreens in Fitzpatrick Skin Phototypes I-VI, Mohsen Mokhtari, Redina Bardhi, Mavra Masood, Deena Abdel-Gadir, Dorothea McGowan, Brittany N. Lane, Marissa Ceresnie, Henry Lim, Iltefat Hamzavi, Indermeet Kohli, and Tasneem Mohammad
52503 The financial burden of scalp cooling therapy: a non-profit organization data analysis, Madison Novice, Taylor Novice, Molly Powers, and Kristen L. Sicco
52509 Expanding access to scalp cooling therapy: a review of post-capping satisfaction in patients who received financial assistance from a non-profit organization, Madison Novice, Lucy Rose, Taylor Novice, Allison Darland, Brittany Dulmage, Molly Powers, and Kristen L. Sicco
